vs

Side-by-side financial comparison of MARCUS CORP (MCS) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $193.5M, roughly 1.0× MARCUS CORP). On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 2.8%). MARCUS CORP produced more free cash flow last quarter ($26.4M vs $17.6M). Over the past eight quarters, MARCUS CORP's revenue compounded faster (18.2% CAGR vs 14.4%).

Marcus & Millichap, Inc. is an American company that provides real estate brokerage, mortgage brokerage, research, and advisory services in the U.S. and Canada in the field of commercial property. It popularized the practice of listing properties exclusively with one brokerage firm. The company has over 1,800 employees in more than 80 offices across the U.S. and Canada.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

MCS vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.0× larger
RGEN
$197.9M
$193.5M
MCS
Growing faster (revenue YoY)
RGEN
RGEN
+10.9% gap
RGEN
13.6%
2.8%
MCS
More free cash flow
MCS
MCS
$8.8M more FCF
MCS
$26.4M
$17.6M
RGEN
Faster 2-yr revenue CAGR
MCS
MCS
Annualised
MCS
18.2%
14.4%
RGEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MCS
MCS
RGEN
RGEN
Revenue
$193.5M
$197.9M
Net Profit
$13.3M
Gross Margin
52.5%
Operating Margin
0.9%
9.0%
Net Margin
6.7%
Revenue YoY
2.8%
13.6%
Net Profit YoY
143.9%
EPS (diluted)
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MCS
MCS
RGEN
RGEN
Q4 25
$193.5M
$197.9M
Q3 25
$210.2M
$188.8M
Q2 25
$206.0M
$182.4M
Q1 25
$148.8M
$169.2M
Q4 24
$188.3M
$174.1M
Q3 24
$232.7M
$154.9M
Q2 24
$176.0M
$154.1M
Q1 24
$138.5M
$151.3M
Net Profit
MCS
MCS
RGEN
RGEN
Q4 25
$13.3M
Q3 25
$16.2M
$14.9M
Q2 25
$7.3M
$14.9M
Q1 25
$-16.8M
$5.8M
Q4 24
$986.0K
$-30.3M
Q3 24
$23.3M
$-654.0K
Q2 24
$-20.2M
$3.3M
Q1 24
$-11.9M
$2.1M
Gross Margin
MCS
MCS
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
MCS
MCS
RGEN
RGEN
Q4 25
0.9%
9.0%
Q3 25
10.8%
8.9%
Q2 25
6.3%
7.6%
Q1 25
-13.7%
3.9%
Q4 24
-1.2%
-17.7%
Q3 24
14.1%
-5.1%
Q2 24
1.3%
1.0%
Q1 24
-12.0%
1.3%
Net Margin
MCS
MCS
RGEN
RGEN
Q4 25
6.7%
Q3 25
7.7%
7.9%
Q2 25
3.6%
8.2%
Q1 25
-11.3%
3.4%
Q4 24
0.5%
-17.4%
Q3 24
10.0%
-0.4%
Q2 24
-11.5%
2.2%
Q1 24
-8.6%
1.4%
EPS (diluted)
MCS
MCS
RGEN
RGEN
Q4 25
$0.24
Q3 25
$0.26
Q2 25
$0.26
Q1 25
$0.10
Q4 24
$-0.55
Q3 24
$-0.01
Q2 24
$0.06
Q1 24
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MCS
MCS
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$23.4M
$767.6M
Total DebtLower is stronger
$159.0M
$542.2M
Stockholders' EquityBook value
$457.4M
$2.1B
Total Assets
$1.0B
$2.9B
Debt / EquityLower = less leverage
0.35×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MCS
MCS
RGEN
RGEN
Q4 25
$23.4M
$767.6M
Q3 25
$7.4M
$748.7M
Q2 25
$14.9M
$708.9M
Q1 25
$11.9M
$697.2M
Q4 24
$40.8M
$757.4M
Q3 24
$28.4M
$784.0M
Q2 24
$32.8M
$809.1M
Q1 24
$17.3M
$780.6M
Total Debt
MCS
MCS
RGEN
RGEN
Q4 25
$159.0M
$542.2M
Q3 25
$162.0M
$537.9M
Q2 25
$179.9M
Q1 25
$198.9M
Q4 24
$159.1M
$525.6M
Q3 24
$173.1M
Q2 24
$175.7M
Q1 24
$169.8M
Stockholders' Equity
MCS
MCS
RGEN
RGEN
Q4 25
$457.4M
$2.1B
Q3 25
$454.3M
$2.1B
Q2 25
$448.4M
$2.1B
Q1 25
$441.8M
$2.0B
Q4 24
$464.9M
$2.0B
Q3 24
$462.3M
$2.0B
Q2 24
$449.4M
$2.0B
Q1 24
$459.3M
$2.0B
Total Assets
MCS
MCS
RGEN
RGEN
Q4 25
$1.0B
$2.9B
Q3 25
$1.0B
$2.9B
Q2 25
$1.0B
$2.9B
Q1 25
$1.0B
$2.9B
Q4 24
$1.0B
$2.8B
Q3 24
$1.0B
$2.8B
Q2 24
$1.1B
$2.9B
Q1 24
$1.0B
$2.8B
Debt / Equity
MCS
MCS
RGEN
RGEN
Q4 25
0.35×
0.26×
Q3 25
0.36×
0.26×
Q2 25
0.40×
Q1 25
0.45×
Q4 24
0.34×
0.27×
Q3 24
0.37×
Q2 24
0.39×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MCS
MCS
RGEN
RGEN
Operating Cash FlowLast quarter
$48.8M
$25.7M
Free Cash FlowOCF − Capex
$26.4M
$17.6M
FCF MarginFCF / Revenue
13.6%
8.9%
Capex IntensityCapex / Revenue
11.6%
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$989.0K
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MCS
MCS
RGEN
RGEN
Q4 25
$48.8M
$25.7M
Q3 25
$39.1M
$48.1M
Q2 25
$31.6M
$28.6M
Q1 25
$-35.3M
$15.0M
Q4 24
$52.6M
$39.2M
Q3 24
$30.5M
$49.3M
Q2 24
$36.0M
$42.2M
Q1 24
$-15.1M
$44.7M
Free Cash Flow
MCS
MCS
RGEN
RGEN
Q4 25
$26.4M
$17.6M
Q3 25
$18.2M
$43.4M
Q2 25
$14.7M
$21.5M
Q1 25
$-58.3M
$11.4M
Q4 24
$27.1M
$33.6M
Q3 24
$12.0M
$42.3M
Q2 24
$16.1M
$37.4M
Q1 24
$-30.5M
$36.4M
FCF Margin
MCS
MCS
RGEN
RGEN
Q4 25
13.6%
8.9%
Q3 25
8.7%
23.0%
Q2 25
7.1%
11.8%
Q1 25
-39.2%
6.8%
Q4 24
14.4%
19.3%
Q3 24
5.2%
27.3%
Q2 24
9.2%
24.3%
Q1 24
-22.0%
24.0%
Capex Intensity
MCS
MCS
RGEN
RGEN
Q4 25
11.6%
4.1%
Q3 25
9.9%
2.5%
Q2 25
8.2%
3.9%
Q1 25
15.5%
2.1%
Q4 24
13.5%
3.2%
Q3 24
7.9%
4.5%
Q2 24
11.3%
3.1%
Q1 24
11.1%
5.5%
Cash Conversion
MCS
MCS
RGEN
RGEN
Q4 25
1.93×
Q3 25
2.41×
3.23×
Q2 25
4.32×
1.92×
Q1 25
2.57×
Q4 24
53.31×
Q3 24
1.31×
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MCS
MCS

Theatres$123.1M64%
Concessions$51.0M26%
Food And Beverage$21.2M11%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons